tiprankstipranks
Catalyst Pharmaceuticals price target raised to $18 from $16 at Piper Sandler
The Fly

Catalyst Pharmaceuticals price target raised to $18 from $16 at Piper Sandler

Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Catalyst Pharmaceuticals to $18 from $16 and keeps an Overweight rating on the shares. Catalyst reported Q3 Firdapse revenues of $57.2M, well ahead of consensus, and increased Firdapse revenue to $205M-$210M, Catanzaro tells investors in a research note. Firdapse continues to grow, driven by a low discontinuation rate and organic growth, including increased enrollment of tumor-LEMS patients, the analyst says.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CPRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles